Summit Shares Jump on AstraZeneca Cancer Deal

Summit Therapeutics shares rose after AstraZeneca announced a two billion dollar investment to jointly test cancer treatments. The collaboration will evaluate experimental therapies for gastrointestinal cancers, providing Summit with significant funding.

Xurve View
Insights:
FILE PHOTO: A company logo is seen at the AstraZeneca site in Macclesfield, Britain, May 11, 2021. REUTERS/Phil Noble/File Photo

Summit Therapeutics shares surged 23% in Tuesday premarket trading after AstraZeneca agreed to a $2 billion investment to co-develop cancer therapies. The deal provides the biotechnology firm with fresh capital while preserving strategic options. It represents a key validation from a major player in oncology.